AbLeads has just concluded a highly productive edition of BioFIT 2025 in Strasbourg, marked by insightful conferences, high-quality discussions, and promising new connections across the European biotech ecosystem.
The event was a great opportunity to present AbLeads’ innovative Dualock Display™ platform, designed to enable the rapid development of personalized anti-cancer antibodies. The concept resonated strongly with attendees, and we received enthusiastic feedback from experts, investors, and potential partners.
BioFIT proved to be an excellent stage to increase AbLeads’ visibility and introduce our vision for next-generation oncology therapeutics. Several key potential partners have already been identified, paving the way for future collaborations as we advance toward our next milestones — including finalizing our technological proof-of-concept and building our antibody development platform prototype.
We are grateful to the organizers, speakers, and all the people we met during these two days of intense exchanges. The momentum gained at BioFIT will help accelerate AbLeads’ mission: develop personalized antibodies to cure low-TMB cancer patients.